Table 2.
Phase II trials included in the analysis with the name of the author, year of publication, number of patients enrolled in the trial, the intervention that was tested and the outcome
| Author | Year | No of patients | Intervention | Outcome for CS patients |
|---|---|---|---|---|
| Merimsky et al.
[23] |
2000 |
18 advanced sarcoma (3 CS) |
Gemcitabine |
2 SD |
| Skubitz et al.
[24] |
2003 |
47 advanced sarcoma (1 CS) |
Pegylated-liposomal doxorubicin |
Not mentioned |
| Nooij et al.
[25] |
2005 |
37 bone sarcoma (16 CS) |
Doxorubicin + cisplatin |
2 CR |
| Group A: operable, non-metastatic (4 CS) |
3 SD |
|||
| Group B: inoperable, metastatic (12 CS) | ||||
| Maki et al.
[26] |
2009 |
145 advanced sarcoma (2 CS) |
Sorafenib (multi-tyrosine kinase inhibitor) |
Not mentioned |
| Pacey et al.
[27] |
2009 |
26 advanced sarcoma (2 CS) |
Sorafenib(multi-tyrosine kinase inhibitor) |
1 SD |
| Grignani et al.
[28] |
2011 |
26 advanced chondrosarcoma |
Imatinib mesylate (c-kit/PDGFR inhibitor) |
8 SD |
| OS 11 months | ||||
| Fox et al.
[29] |
2012 |
53 advanced sarcoma (25 CS) |
Gemcitabine + docetaxel |
2 PR |
| Italiano et al.
[30] |
2012 |
40 advanced CS |
GDC-0449/vismodegib (hedgehog inhibitor) |
4 SD (of first 17 patients) |
| Schuetze et al.
[31] |
2012 |
49 advanced sarcoma (2 CS) |
Sirolimus (mTOR inhibitor) + cyclophosphamide |
1 SD |
| Ha et al.
[32] |
2013 |
36 advanced sarcoma |
Cetuximab (EGFR antibody) |
PD |
| Group A: EGFR+ | ||||
| Group B: EGFR- (1 CS) | ||||
| Schwartz et al.
[33] |
2013 |
388 advanced sarcoma |
Cixutumumab (IGF1R antibody) + temsirolimus (mTOR-inhibitor) |
Not mentioned |
| Group A: IGF-1R + soft tissue sarcoma | ||||
| Group B: IGF-1R + bone sarcoma (20 CS) | ||||
| Group C: IGF-1R- sarcoma (18 CS) |
CR complete response, CS chondrosarcoma, OS overall survival, PD progressive disease, PFS progression free survival, PR partial response, SD stable disease.